<?xml version="1.0" encoding="UTF-8"?>
<p>The EAC MRH initiative is already tracking time from application receipt to approval, or total assessment time [
 <xref rid="pmed.1003092.ref003" ref-type="bibr">3</xref>]. By continuing to define target timelines for key milestones in the joint assessment process, developing formal processes for routinely monitoring relevant metrics, and making the resulting data public [
 <xref rid="pmed.1003092.ref021" ref-type="bibr">21</xref>], the EAC MRH initiative can increase its efficiency and promote trust among stakeholders. Establishing a framework in which timely, high-quality assessments are the norm will result in safe and effective medicines reaching the market sooner, while unsafe or ineffective medicines are promptly denied approval.
</p>
